GlassScriptPhysician profile
Alan T Rauba
NPI 1568442267
$593,719.98
in general payments reported to CMS, 2019-2025
57 companies · $68K in 2025
The $68K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169K · 2020: $69K · 2021: $64K · 2022: $92K · 2023: $71K · 2024: $62K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $185K · Travel and Lodging: $9,526 · Food and Beverage: $5,332 · Education: $29.12 · Consulting Fee: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,347.69 |
| Travel and Lodging | $9,525.67 |
| Food and Beverage | $5,332.25 |
| Education | $29.12 |
| Consulting Fee | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290,627.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $212,681.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $69,618.39 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,757.96 | 2019-2023 | Jardiance |
| Tandem Diabetes Care, INC. | $1,811.45 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $824.27 | 2019-2025 | Repatha, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $494.72 | 2021-2024 | |
| Abbvie INC. | $367.30 | 2019-2024 | |
| Abbott Laboratories | $349.81 | 2019-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $300.72 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $295.81 | 2019-2023 | |
| Amarin Pharma, INC. | $282.01 | 2019-2022 | |
| Esperion Therapeutics, INC. | $208.86 | 2020-2024 | Nexletol |
| Glaxosmithkline, LLC. | $208.41 | 2022-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $190.40 | 2019-2024 | Dexcom G6 Transmitter |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Rauba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.